The physostigmine controversy  by Brossi, Arnold R
Volume 252, number 1,2, 159 FEB 07437 July 1989 
Reply to comment 
De bello physostigminico II 
(The physostigrnine controversy) 
Arnold R. Brossi 
National Institutes of Health, Building 8, Room Bl-23. Bethesda, MD 20205, USA 
Received 30 May 1989 
We started working on physostigmine in 1984 
and our first presentation on a successful new par- 
tial synthesis was given at the University of North 
Carolina in Chapel Hill in July of 1985 [(1985) J. 
Nat. Prod. 48,878-8931. Although we reported N- 
methylphysostigmine to be an oil which was fully 
characterized and more potent in vitro than (-)- 
physostigmine in the inhibition of AChE, we later 
found that ( - )-N-methylphysostigmine was a 
crystalline compound [( 1987) Heterocycles 26, 
1271-12751 and much less potent in the assay now 
performed in a different laboratory by a different 
investigator [(1988) FEBS Lett. 234, 127-1301. We 
were at that time unaware that this compound had 
been described by Whelpton and Moore [(1985) J. 
Chromatogr. Biomed. Appl. 341, 361-3711. 
Our including octylcarbamoyleseroline among a 
series of carbamates to be compared with ( -)- 
physostigmine without mentioning the heptyl 
analog made by Italian investigators, was an over- 
sight on our part. Dr Pompom’s remark that we 
did not mention the differences observed in our 
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paper [(1988) FEBS Lett. 234, 1291 is untrue and 
not citing work done by the two parties equally ap- 
plies to Dr Pompom’s paper in Life Sciences 
[(1988) Life Sci. 43, 1921-19281 which was receiv- 
ed in final form in October of 1988 and, therefore, 
could well have mentioned our work which was 
published in July. 
It will always be difficult for scientists working 
competitively in different countries to keep track 
of every paper published on the subject. To cite pa- 
tent applications is impossible since one does not 
know who applied for what and where, and even 
patents if issued take time to be recognized. We 
have continued working in the field [e.g., (1988) J. 
Med. Chem. 31, 2297-2300 and (1989) J. Phar- 
macol. Exp. Therap. 249, 194-2021. It is hoped 
that this work will ultimately provide improved 
drugs for the treatment of geriatric disorders and 
will continue in many places. After all, patients do 
not really care whether a drug is developed in 
Switzerland, Italy or America. 
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